PE20140909A1 - COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT - Google Patents

COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT

Info

Publication number
PE20140909A1
PE20140909A1 PE2014000295A PE2014000295A PE20140909A1 PE 20140909 A1 PE20140909 A1 PE 20140909A1 PE 2014000295 A PE2014000295 A PE 2014000295A PE 2014000295 A PE2014000295 A PE 2014000295A PE 20140909 A1 PE20140909 A1 PE 20140909A1
Authority
PE
Peru
Prior art keywords
compounds
imidazo
pyridine
inhibitors
oxadiazol
Prior art date
Application number
PE2014000295A
Other languages
English (en)
Spanish (es)
Inventor
Valentina Molteni
Hank Michael James Petrassi
Xiaolin Li
Xiaodong Liu
Jon Loren
Juliet Nabakka
Bao Nguyen
Vince Yeh
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of PE20140909A1 publication Critical patent/PE20140909A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2014000295A 2011-09-01 2012-08-29 COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT PE20140909A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161530038P 2011-09-01 2011-09-01

Publications (1)

Publication Number Publication Date
PE20140909A1 true PE20140909A1 (es) 2014-07-20

Family

ID=46829904

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000295A PE20140909A1 (es) 2011-09-01 2012-08-29 COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT

Country Status (30)

Country Link
US (3) US8569283B2 (cg-RX-API-DMAC7.html)
EP (1) EP2751104B1 (cg-RX-API-DMAC7.html)
JP (1) JP6134319B2 (cg-RX-API-DMAC7.html)
KR (1) KR101962495B1 (cg-RX-API-DMAC7.html)
CN (1) CN103797011B (cg-RX-API-DMAC7.html)
AP (1) AP2014007493A0 (cg-RX-API-DMAC7.html)
AR (1) AR087753A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012302042B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014004560A2 (cg-RX-API-DMAC7.html)
CA (1) CA2845169C (cg-RX-API-DMAC7.html)
CL (1) CL2014000492A1 (cg-RX-API-DMAC7.html)
CO (1) CO6900141A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140107A (cg-RX-API-DMAC7.html)
CU (1) CU20140024A7 (cg-RX-API-DMAC7.html)
EA (1) EA026152B1 (cg-RX-API-DMAC7.html)
ES (1) ES2761332T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400034A (cg-RX-API-DMAC7.html)
IL (1) IL231227A0 (cg-RX-API-DMAC7.html)
MA (1) MA35460B1 (cg-RX-API-DMAC7.html)
MX (1) MX339937B (cg-RX-API-DMAC7.html)
PE (1) PE20140909A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500372A1 (cg-RX-API-DMAC7.html)
PL (1) PL2751104T3 (cg-RX-API-DMAC7.html)
PT (1) PT2751104T (cg-RX-API-DMAC7.html)
SG (1) SG2014014369A (cg-RX-API-DMAC7.html)
TN (1) TN2014000068A1 (cg-RX-API-DMAC7.html)
TW (1) TW201313717A (cg-RX-API-DMAC7.html)
UY (1) UY34301A (cg-RX-API-DMAC7.html)
WO (1) WO2013033167A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201401175B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
UY34301A (es) 2011-09-01 2013-04-05 Irm Llc COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
US20150288928A1 (en) * 2014-04-08 2015-10-08 Sony Corporation Security camera system use of object location tracking data
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN108235704B (zh) 2015-07-02 2021-10-26 爱尔兰詹森科学公司 抗细菌化合物
US10474987B2 (en) * 2015-08-05 2019-11-12 Whirlpool Corporation Object recognition system for an appliance and method for managing household inventory of consumables
WO2017214413A1 (en) * 2016-06-08 2017-12-14 Chrysalis, Inc. Imidazo[1,2-a]pyridine derivatives as histone demethylase inhibitors
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
BR112018075939A2 (pt) 2016-06-16 2019-04-09 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
AU2017348354B2 (en) 2016-10-27 2023-06-15 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
US20180162291A1 (en) * 2016-12-12 2018-06-14 Wipro Limited System and method of dynamically adjusting field of view of an image capturing device
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy
DK3618875T3 (da) 2017-05-02 2023-07-10 Novartis Ag Kombinationsterapi omfattende en raf-inhibitor og trametinib
AU2018358160B2 (en) 2017-11-02 2023-03-16 Abbvie Inc. Modulators of the integrated stress pathway
KR102625224B1 (ko) * 2018-10-31 2024-01-15 주식회사 큐로젠 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
TW202108581A (zh) * 2019-05-13 2021-03-01 瑞士商諾華公司 N-(5-(5-((1r,2s)-2氟環丙基)-1,2,4-㗁二唑-3-基)-2-甲基苯基)咪唑并[1,2-a]吡啶-3-甲醯胺之結晶型
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
WO2021035788A1 (zh) 2019-08-29 2021-03-04 中国科学院合肥物质科学研究院 吡唑衍生物及其用途
ES2978573T3 (es) 2019-09-13 2024-09-16 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4181921A4 (en) 2020-07-15 2025-02-26 Third Harmonic Bio, Inc. CRYSTALLINE FORMS OF A SELECTIVE C-KIT KINASE INHIBITOR
WO2022109595A1 (en) * 2020-11-19 2022-05-27 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
WO2022194803A1 (en) 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
BR112023018655A2 (pt) 2021-03-17 2023-12-12 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
WO2022194906A1 (en) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
KR20240090864A (ko) 2021-10-28 2024-06-21 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 세균성 감염의 치료에 사용하기 위한 이미다조피리딘 아미드 및 관련 화합물
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
KR20250121029A (ko) * 2022-11-30 2025-08-11 블루프린트 메디신즈 코포레이션 두드러기 치료를 위한 야생형 c-kit 키나제 억제제로서의 n-페닐-피라졸로[1,5-a]피리딘-3-카르복사미드 유도체
WO2024124002A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024123966A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025072330A1 (en) * 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004001903A2 (en) 2002-06-20 2003-12-31 Beacon Looms, Inc. Knitted electrical conductor fabric
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
AU2005281299B2 (en) 2004-09-09 2012-03-15 Natco Pharma Limited Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
EP1835934A4 (en) 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc ENZYME MODULATORS AND TREATMENTS
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
US20100048539A1 (en) * 2006-11-03 2010-02-25 Irm Llc Compounds and compositions as protein kinase inhibitors
JP6117104B2 (ja) * 2010-11-15 2017-04-19 アッヴィ・インコーポレイテッド Namptおよびrock阻害薬
US20130023751A1 (en) 2011-07-18 2013-01-24 Samuel Victor Lichtenstein Water retention monitoring
EA201490539A1 (ru) 2011-09-01 2014-06-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов c-kit киназы
UY34301A (es) 2011-09-01 2013-04-05 Irm Llc COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
AU2012301675A1 (en) 2011-09-01 2014-03-13 Irm Llc Compounds and compositions as PDGFR kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors

Also Published As

Publication number Publication date
GT201400034A (es) 2015-02-19
JP2014525448A (ja) 2014-09-29
CO6900141A2 (es) 2014-03-20
US8569283B2 (en) 2013-10-29
KR20140075692A (ko) 2014-06-19
CN103797011A (zh) 2014-05-14
CA2845169C (en) 2022-04-19
US9023839B2 (en) 2015-05-05
US20140031333A1 (en) 2014-01-30
PT2751104T (pt) 2019-12-16
US20140228347A1 (en) 2014-08-14
MX339937B (es) 2016-06-17
ES2761332T3 (es) 2020-05-19
CA2845169A1 (en) 2013-03-07
CU20140024A7 (es) 2014-04-24
UY34301A (es) 2013-04-05
EP2751104B1 (en) 2019-09-25
JP6134319B2 (ja) 2017-05-24
EA026152B1 (ru) 2017-03-31
PL2751104T3 (pl) 2020-04-30
TN2014000068A1 (en) 2015-07-01
ZA201401175B (en) 2015-01-28
MA35460B1 (fr) 2014-09-01
US8754071B2 (en) 2014-06-17
CN103797011B (zh) 2016-03-30
PH12014500372A1 (en) 2014-04-07
EP2751104A1 (en) 2014-07-09
EA201490545A1 (ru) 2014-07-30
CL2014000492A1 (es) 2014-10-03
AP2014007493A0 (en) 2014-03-31
IL231227A0 (en) 2014-04-30
MX2014002484A (es) 2014-11-25
AR087753A1 (es) 2014-04-16
WO2013033167A1 (en) 2013-03-07
AU2012302042A1 (en) 2014-04-17
SG2014014369A (en) 2014-09-26
US20130059832A1 (en) 2013-03-07
BR112014004560A2 (pt) 2017-04-04
AU2012302042B2 (en) 2016-03-31
TW201313717A (zh) 2013-04-01
CR20140107A (es) 2014-05-02
KR101962495B1 (ko) 2019-03-26

Similar Documents

Publication Publication Date Title
PE20140909A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT
PE20141033A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KIT
PE20141059A1 (es) Indazoles
PE20161475A1 (es) Pirazolopiridinas y pirazolopirimidinas
PE20160540A1 (es) Inhibidores de bromodominios
PE20120321A1 (es) Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
PE20091828A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
MX2012015120A (es) Derivados de imidazopiridina, su procedimiento de preparación y su uso en terapeutica.
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk
EP4295841A3 (en) Sulfur (vi) fluoride compounds and their use in click-reaction
PE20091972A1 (es) Compuestos heterociclicos como inhibidores del factor ixa
PE20140832A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
PE20170663A1 (es) Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
PE20170303A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
AR087870A1 (es) Derivados 5-fluoro pirimidina disustituidos que contienen un grupo sulfoximina
PE20120056A1 (es) Derivados de indol como antagonistas del receptor crth2
MX377581B (es) Compuestos antihelmínticos y composiciones y método de uso de los mismos.
BR112013009580A2 (pt) composto de fómrula (i), composição fungicida e método para controlar fungos fitopatogênicos
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
SG195106A1 (en) Trpv4 antagonists
PE20130246A1 (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SINTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO

Legal Events

Date Code Title Description
FA Abandonment or withdrawal